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Alterations in blood and tissue concentrations of trace ele-
ments in the uremic patient have been investigated extensively
over the last few years. These studies have largely been
undertaken in patients with chronic renal failure (CRF) who
were not on dialysis or with endstage renal failure (ESRF) on
recurrent hemodialysis (HD). The most outstanding abnormali-
ty detected was the blood and tissue accumulation of aluminum
[1—13]. High concentrations of aluminum have been linked with
the development of dialysis dementia [2, 4, 5, 7, 8, 11, 13] and
bone disease [1, 12, 13]. In patients with CRF who were not on
dialysis increased tissue concentrations of zinc (bone and heart)
[61, arsenic (bone and brain) [6], lead (bone, brain, and spleen)
[61, and aluminum were described [6, 10, 11], although rubidium
was found to be reduced [6]. In patients on hemodialysis normal
or increased plasma and tissue concentrations of magnesium,
aluminum, calcium, iron, strontium, molybdenum, cesium, and
cadmium were detected although some patients exhibited re-
duced concentrations of selenium and rubidium [6, 14, 151.
However, various serum concentrations of zinc have been
reported as low [16—191, normal [15], or high [14, 20—22]. Serum
and tissue copper concentrations have been reported usually as
normal or elevated [9, 15, 22, 23]. On the other hand, cases of
acute zinc [24, 25], nickel [6], and copper [26] toxicity due to a
leaching of these metals from dialysis plumbing have been
described.
The possible causes of altered blood and tissue concentra-
tions of trace elements include: failure of renal excretion of
elements normally taken in the diet, increased oral intake of
elements (for example, aluminum in aluminum hydroxide medi-
cation for phosphate retention), contamination of dialysate by
trace elements, and loss of trace elements across the dialysis
membrane. Considerable variation in tissue concentrations of
trace elements are to be expected according to whether local
water supplies and soils contain low or high concentrations of
each element and whether water for dialysate is simply filtered
or treated by de-ionization or reverse osmosis. This is best
exemplified by the correlation of serum aluminum concentra-
tions in patients on hemodialysis with water supply concentra-
tions [12, 13].
The increased use of intermittent peritoneal dialysis (IPD)
and more recently continuous ambulatory peritoneal dialysis
(CAPD) in the treatment of patients with end stage renal failure
has indicated the need to expand these studies of trace elements
to patients on peritoneal dialysis. Theoretically, peritoneal
dialysis could lead to a greater depletion of elements than
hemodialysis because most elements are protein bound and
considerable peritoneal protein loss can occur. On the other
hand, the volume of dialysate to which the patient is exposed is
less for peritoneal dialysis than hemodialysis, perhaps reducing
the absorption of potentially toxic elements.
Therefore, we studied trace element concentrations in the
blood of patients on CAPD and IPD and compared the concen-
trations to those in normals, patients with CRF but not on
dialysis, and patients on recurrent hemodialysis.
Methods
Patients. Since June 1978, 68 patients with ESRF have been
trained in CAPD. The clinical features of these patients, ade-
quacy of dialysis, and complications experienced have been
reported previously [27—29]. Of the 52 patients on CAPD for at
least 3 months, 31 were assessed on one or more occasions for
blood concentrations of trace elements. Over the same period
trace element concentrations were also assessed in 162 normal
people, 71 patients with CRF but not on dialysis, 44 patients on
recurrent hemodialysis, and 10 patients on IPD [30]. The
characteristics of these patient groups are shown in Table 1.
The causes of renal failure in each group were similar except
that diabetics comprised 14% of the patients on CAPD but none
of those on IPD or hemodialysis. Studies were undertaken with
the patients in a stable state and on each type of dialysis for at
least 3 months. Nondiabetic patients were on normal diets
except for salt and potassium restriction when indicated and
with vitamin, folic acid, and iron supplements. All patients with
CRF, on hemodialysis, or IPD required aluminum hydroxide
therapy (Alutabs, 600 mg/tab), but this was needed in only 72%
of the patients on CAPD. Patients on CAPD received 4 or 5 2-
liter exchanges of dialysate (Dianeal, Travenol, Sydney, Aus-
tralia) per day while those on IPD were dialyzed with the same
dialysate for 20 exchanges three times per week. Hemodialysis
was performed for 4 to 6 hr three times per week using high
performance parallel plate or hollow fibre dialyzers with blood
flow rates of 200 ml/min and dialy sate flow rates of 500 ml/min.
Water for hemodialysis was filtered through membranes with
pores of 1 m but not subjected to purification by de-ionization
or reverse osmosis.
Elements. The elements studied were copper (Cu), zinc (Zn),
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Table 1. Characteristics of patient groups
Patient group
CRF
(Not on dialysis)
CAPD
IPD
1-temodialysis
71 1.6/1
3!
l0
44
Age: Mean
Range, years
33.5 (19 to 60)
39.6 (14 to 64)
0.8/1 42.8 (6 to 74)
1/1 45.2 (22 to 66)
1.7/1 38.4 (13 to 70)
Time on treatment
Mean range, months
13.5 (3 to 34)
10.5 (4 to 46)
15.2 (3 to 52)
Aluminum
Plasma, gino/es/liter
Manganese
Plasma, nmoles/liter
Cadmium
Whole blood, orioles/liter
Lead
Red cell, gino/es/liter
Chromium
Whole blood, orioles/liter
p 0.05
"P < 0.02
P C 0.01
P < 0.001
<0.74 6.9 (± 3.8)d
68.4 (- 32.2) 80.4 (± 49.1)"
32.2 (± 8.2)
2.02)± 1.08)
18.5 (± 11.1)"
2.58 (t 1.94)"
70 (± 20) 60 (± 60) 160
66.7 (± 33.2)
22.3 (± 14.2)"
2.53)± 1.12)
(± 2l0)
10.9 (± 5.9)"
2.36 (± 1.82)
70 (± 50)
28.6(± 10.8)
2.4 (± 0.87)
160 (± 55)d
aluminum (Al), manganese (Mn), lead (Pb), cadmium (Cd), and
chromium (Cr). Plasma was assayed for Cti, Zn, Al, and Mn,
red cells for Cu, Pb and Zn, and whole blood for Cd, and Cr. Tn
isolated patients other tissues (for example, bone, muscle, liver,
spleen, and brain) were also studied, but these observations are
insufficient in number for meaningful analysis.
Processiog of samples and analysis of elements. Blood
samples were drawn in syringes and needles which were batch-
tested and shown not to contribute metal contamination. Blood
was placed in polystyrene tithes which had been soaked in
detergent, rinsed and soaked again in 20% nitric acid for a
minimum of 5 hr before final rinsing and drying. Heparin was
used as an anticoagulant and shown to he metal free. All
associated glassware was also cleaned by the method de-
scribed. Plasma was separated from red cells as soon as
possible after blood collection. Where measurement was made
on red cells, the cells were washed twice with normal saline
before analysis. All measurements were carried out on a Varian
Tcchtron AA-5 atomic absorption spectrophotometer. Copper
and zinc in plasma and red cells were measured by a flame
method. Other metals were measured by direct application of
micro volumes to a model CRA 63 graphite cup, with standard-
ization performed by the method of additions.
Analysis of results. A statistical comparison between patient
groups was undertaken using the Wilcoxon rank test for two
samples [31].
Results
Zinc (Table 2, Fig. I). A slight but significant reduction was
seen in plasma zinc concentrations in patients on CAPD (P <
0.05) and IPD (P < 0.05) but not in patients with CRF or on
hemodialysis. This reduction was abolished when adjustment
was made for serum albumin concentrations. The mean serum
albumin concentrations in patients on CAPD and IPD were 34.2
Number
in group
Normals 162 1/1
Male/Female
LIe rsicnt
Zinc
Plasma, gino/es/liter
Red cell, p.moles/liter
Copper
Plasma. j.rmoles/liter
Red cell, ).tmoles/liter
Table 2. Trace element concentrations in each patient group, mean (± sn)
Normals CRF Heoiodialysis IPD(N 162) (N-76) )N=44) )N— 10)
15.1 (t 3.6)
191 (± 61)
19.1 )± 5.9)
15.0 (± 4.2)
13.3 (± 4.4)"
165 )± 46)"
2)1.1 (± 5.4)
12.8 / 4.0)"
14.9 (± 6.0)
134 (t 62)"
21.1 (-- 8.0)
12.5 (± 4.5)"
12.3 (± 45)"
188 (± 79)
21.1 (± 9.3)
12.1 /± 5.0)"
CAPD
(N 31)
12.6% 3.5)
104.5 (± 35)"
17.5 (± 7.5)
7.8 (± 3.5)"
3.9 (± 1.7)"6.8 (-t 3.3)" 5.1 )± 2.6)"
76.9 (± 41.0) 76.5 ( 21)
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glliter (range, 23 to 41 g/liter) and 34.9 g!liter (range, 25 to 39 g/
liter), respectively, which compared to 37.0 g/liter (range, 31 to
45 glliter) and 39.6 g!liter (range, 32 to 48 g/liter) in patients with
CRF and patients on hemodialysis, respectively. Red cell zinc
concentrations were markedly reduced (P < 0.001) in patients
on CAPD; the mean concentration of 104.5 moles/liter indicat-
ed a reduction of 46% of normal concentrations. This degree of
reduction was evident within 4 months of commencing CAPD
but did not increase with further time on CAPD. Red cell zinc
concentrations in patients on IPD were not significantly re-
duced, but a 13 and 29% reduction was seen in patients with
CRF and in patients on hemodialysis, respectively.
Copper (Table 2, Fig. 2). Plasma copper concentrations were
normal in all groups of patients. A mild but significant reduction
in red cell copper was seen in patients with CRF (13%), patients
on hemodialysis (16%), and patients on IPD (19%). However,
red cell copper concentrations in patients on CAPD were
reduced markedly (by 48% compared to normals and by 36%
compared to the hemodialysis group). Again this degree of
reduction of red cell copper was in evidence by 3 to 4 months
after beginning CAPD and did not fall further with additional
time on CAPD.
Aluminum (Table 2, Fig. 3). Plasma aluminum concentrations
were elevated in all patients in all groups. Two patients (3%)
with CRF and three patients (7%) on hemodialysis had concen-
trations in excess of 12 moles/liter (320 LgIliter), a concentra-
tion above which dialysis dementia and aluminum bone disease
may develop. Two of the hemodialysis patients developed fatal
dialysis dementia. Although plasma aluminum rose in patients
on IPD and CAPD, concentrations were significantly less than
in patients with CRF and patients on hemodialysis. No patient
on IPD or CAPD had an aluminum concentration greater than 8
moles/liter (240 p.g/liter). Plasma concentrations of aluminum
did not change with time on CAPD. The mean concentration at
4 to 6 months was 4.1 moles/liter (range, 1.5 to 6.8 imoles/
liter) and at 20 to 24 months, 3.6 tmoles/liter (1.0 to 6.4 moles/
liter). The mean concentration of aluminum in five patients who
had not received aluminum hydroxide therapy for at least 3
months was only 1.6 molesIliter (range, 0.8 to 2.5 moles/liter)
which was a concentration significantly less (P = 0.05) than that
NSP<0.01 NSP<0.05 NSP 0.05 NSP<0.001
cf PD
P<0.01
Normals CR F Hemodialysis Intermittent CAPD
(N= 162) (N=76) (N=44) P.O. )N=31:N= 13)(N= 10)
Fig. 2. Plasma (I) and red cell (I) copper concentrations in each
patient group; mean SD.
of patients receiving between 2.4 and 3.6 g of aluminum
hydroxide per day (Fig. 4). However, a difference was not seen
in concentrations of aluminum between patients on less than 3.6
g of aluminum hydroxide per day and those on more than 7.2 g
per day.
Preliminary observations of aluminum concentrations in pen-
toneal dialysate revealed a wide range of concentrations from
less than 0.4 moles/liter (10 .tg/liter) to more than 2.0 moles/
liter (50 tgIliter). However, how much of this is nonabsorbable
particulate aluminum and how much is soluble is yet to be
determined.
Manganese, lead, and cadmium (Table 2, Fig. 5). Concentra-
tions of these elements in patients on CAPD were not signifi-
cantly different from normals. Patients with CRF, those on
hemodialysis, and those on IPD showed a significant reduction
(P < 0.001) in whole blood cadmium. However, with time on
hemodialysis cadmium concentrations rose so that patients on
hemodialysis for more than 6 months had normal cadmium
concentrations. Plasma manganese concentrations were in-
creased slightly (P < 0.05) in patients with CRF but were
normal in hemodialysis and IPD patients. Significant but slight
rises in concentrations of red cell lead were seen in patients
with CRF (27% rise) and patients on hemodialysis (25%).
Chromium (Table 2, Fig. 5). Whole blood chromium concen-
trations were elevated to about twice normal in patients on
CAPD and hemodialysis but were normal in patients with CRF
or on IPD.
Discussion
Although many studies have been published concerning trace
element concentrations in patients with CRF or on hemodialy-
sis, very few have focused on patients on IPD [19, 23].
Moreover, to our knowledge, there are only two reports of trace
elements in patients on CAPD, dealing with only one and five
patients, respectively [32, 33]. This latter study [33] showed
normal serum concentrations of zinc, copper, and fluoride and
increased concentrations of aluminum. In our study of 31
patients who were on CAPD for at least 3 months we defined a
number of important alterations in trace metal concentrations in
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Fig. 1. Plasma (I) and red cell zinc (I) concentrations in each patient
group; mean SD.
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Fig. 3. Plasma aluminum concentrations in each patient group; mean
si. The concentration above which dialysis dementia may occur is
indicated by )
the blood and were able to compare these alterations to those
seen in similarly studied patients with CRF but not on dialysis,
those on hemodialysis, and those on intermittent peritoneal
dialysis.
The most prominent abnormality in patients in CAPD was a
marked reduction in red cell concentrations of zinc and copper
although plasma concentrations (when adjusted for albumin
concentrations) were normal. A mild to moderate reduction of
red cell zinc and copper was also seen in patients with CRF and
on hemodialysis, and copper was also reduced in patients on
IPD. However, deficiency of zinc and copper in these latter
three groups of patients was not to the degree seen in patients
on CAPD. Both zinc and copper are vital elements for normal
metabolism [34], Zinc deficiency may cause weakness, anorex-
ia, taste disturbance (hypogeusia), iron deficiency anemia,
hepatosplenomegaly, dwarfism, and hypogonadism [35, 36].
The biochemical changes, particularly increased plasma ammo-
nia and ribonuclease activity, which have been reported in
experimentally induced zinc deficiency in man and animals [37,
381 have been reported in patients on hemodialysis with low
serum zinc concentrations [19]. The clinical significance of zinc
deficiency in our patients on CAPD is unknown. Weakness,
anorexia, and taste disturbances are symptoms not uncommon
in patients on CAPD. We were unable to correlate the degree of
zinc depletion in our patients on CAPD with the presence of
these symptoms. Acrodermatitis enteropathica, a feature of
severe zinc deficiency, was not seen in any patient on CAPD.
Similarly, the significance of the copper depletion is unknown.
Copper deficiency may he associated with anemia which may
be megaloblastic or sideroblastic and leucopoenia. Significant
leucopoenia (<4000 cells/mm3), was seen in four patients on
CAPD hut did not correlate with the degree of copper depletion.
Two patients on CAPD have shown macrocytic features of
peripheral blood erythrocytes in the presence of normal serum
vitamin B12 and folic acid concentrations.
The mechanism(s) by which zinc and copper depletion may
occur in CAPD is yet to be studied. Both elements are protein-
bound in the circulation (zinc to albumin, copper to ceruloplas-
mm) and loss into the peritoneum is possible. However, a
correlation between the quantity of protein in the 24-hr effluent
dialysate and red cell concentrations of zinc or copper was not
demonstrable. Whether or not other tissues apart from red cells
are similarly depleted of zinc and copper will depend on future
studies.
Patients on CAPD and IPD have shown increased plasma
concentrations of aluminum but not to the degree seen in
patients with CRF or on hemodialysis. The highest concentra-
tions in CAPD patients were seen in patients on aluminum
hydroxide therapy, strongly suggesting that oral aluminum
hydroxide is an important, if not the most important, source of
plasma aluminum in these patients. It has been previously
shown by others that serum aluminum concentrations in pa-
tients with CRF and not on dialysis, may be correlated similarly
with oral aluminum hydroxide therapy [6, 10, II, 391. Our
patients with CRF and those on hemodialysis were taking
considerably larger doses of aluminum hydroxide than patients
on CAPD. As we have previously reported, patients starting on
CAPD were able to reduce the daily dose of aluminum hydrox-
ide by 60 to 100% of the dose required to control hyperphospha-
temia while not on dialysis [28]. Other possible factors causing
high aluminum concentrations in patients on CAPD include
accumulation before beginning dialysis and the absorption of
aluminum from the peritoneal dialysate. Peritoneal dialysate
used in our patients certainly contains aluminum often at high
concentration. However, the proportion of aluminum that is
soluble and thus available for absorption is unknown. On the
other hand, loss of aluminum (even protein bound) into the
dialysate may be a mechanism for removal of excessive alumi-
num from the body. Aluminum is particularly bound to albumin
and two other smaller molecular weight proteins [40].
Our patients on hemodialysis showed a considerable accumu-
lation of aluminum resulting in death in two patients from
dialysis dementia. The water supply of Melbourne, after pas-
sage through a 0.45-pr filter, contains aluminum at a concentra-
tion varying from < 0.7 jxmole/liter (20 jsg/liter) to 37 Mmoles/
liter (1000 jzg/liter) depending on which reservoir is in use. This
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has led to a radical reappraisal of the need to use reverse
osmosis for the preparation of water for hemodialysis. Howev-
er, the expense involved may be prohibitive. Therefore, in
regard to preventing aluminum toxicity, peritoneal dialysis,
particularly CAPD, has a major advantage over hemodialysis.
Alterations of manganese, lead, and cadmium concentrations
were not seen in patients on CAPD. The significant reduction in
whole blood cadmium in patients with CRF, or on hemodialysis
or IPD is difficult to explain but probably clinically unimpor-
tant. Our results differ with Alfrey et al [61 who demonstrated
slight rises in cadmium. We and other observers found a
significant increase in lead concentrations in CRF and hemodi-
alysis patients [61. However, these concentrations are also
unlikely to be clinically important. The cause of increased
chromium concentrations in patients on CAPD and hemodialy-
sis may be related to dialysate contamination by this element.
Cornelis et a! [32] who studied one patient on CAPD, found a
serum chromium concentration 23 times normal and a dialysate
concentration 10 times that of normal serum.
In conclusion our studies have shown marked depletion of
red cell copper and zinc in patients on CAPD while aluminum
concentrations, although increased, are significantly lower than
in patients on hemodialysis. All the observations in this report
concern blood concentrations of trace elements. Studies cur-
rently underway involve observations of tissue concentrations
of these elements in patients on CAPD. Additional studies are
being made to determine trace element concentrations in dialy-
sate and effluent dialysis to assess the importance of absorption
or loss of elements through the peritoneal membrane, in the
development of accumulation or depletion states.
Summary. Comparison of trace elements in peritoneal dialy-
sis, hemodialysis, and uremia. The accumulation of trace
elements, particularly aluminum, in patients on recurrent hemo-
dialysis has been well described. However few studies of
patients on recurrent peritoneal dialysis have been undertaken.
In this study we examined the concentrations of zinc, copper,
aluminum, manganese, lead, cadmium, and chromium in the
blood of 31 patients on continuous ambulatory peritoneal
dialysis (CAPD) and 10 patients on intermittent peritoneal
dialysis (IPD) comparing the results with concentrations in 162
normal people, 71 patients with chronic renal failure but not on
dialysis, and 44 patients on recurrent hemodialysis. Elements
ations were seen in the other patient groups. Chromium concen-
trations were increased to twice normal in CAPD and hemodial-
ysis patients. The clinical significance of red cell copper and
zinc depletion in CAPD has not yet been determined. The
depletion mechanism of these two elements and of the accumu-
lation of aluminum in CAPD patients is currently being
investigated.
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